Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Exelixis Inc's Business Segments
Exelixis Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 611
Regions Reported
1
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 611 | 100% |
Revenue Share by Region - Q1 FY2026
- Europe6.5%
Revenue by Geographic Region - Q1 FY2026
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Europe | $ 40 | 6.5% |
Revenue by Product & Service Category - Q1 FY2026
- Product, Gross0%
- Product90.9%
- CABOMETYX90.5%
- License9.3%
- Collaboration9.1%
- COMETRIQ0.4%
- Service0%
- Product, Sales Discounts and Allowances0%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product, Gross | $ 795 | - |
| Product | $ 555 | 90.9% |
| CABOMETYX | $ 553 | 90.5% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
5 more categories available
Sign in to unlock the full Exelixis Inc dataset.
Description of Exelixis Inc
Exelixis Inc.
is a biopharmaceutical company headquartered in Alameda, California, United States.
The company was founded in 1994, and it develops and commercializes proprietary therapeutics for the treatment of cancer and other serious diseases.
Exelixis has a diverse pipeline of small molecule therapeutics that are designed to address various types of cancer.
Its lead product, cabozantinib, is an inhibitor of multiple tyrosine kinases, including MET, VEGF receptors, AXL, RET, and ROS1.
Cabozantinib targets cancer cells in multiple ways and has demonstrated significant clinical benefits across several indications, including renal cell carcinoma, hepatocellular carcinoma, and advanced prostate cancer.
Apart from cabozantinib, Exelixis also has several other product candidates in its pipeline, including XL092, which is currently in Phase 1 clinical trials for the treatment of solid tumors, and XL102, which is being developed for the treatment of hematologic malignancies.
Exelixis has partnerships with several leading pharmaceutical companies, including Bristol Myers Squibb, Roche, and Merck.
These collaborations are aimed at advancing the development and commercialization of its small molecule therapeutics in various markets around the world.
Overall, Exelixis is a leading player in the field of cancer therapeutics, with a strong focus on innovation, research, and development.
The company is committed to improving the lives of patients with cancer and other serious diseases, and it is well-positioned to continue its growth trajectory in the coming years.
is a biopharmaceutical company headquartered in Alameda, California, United States.
The company was founded in 1994, and it develops and commercializes proprietary therapeutics for the treatment of cancer and other serious diseases.
Exelixis has a diverse pipeline of small molecule therapeutics that are designed to address various types of cancer.
Its lead product, cabozantinib, is an inhibitor of multiple tyrosine kinases, including MET, VEGF receptors, AXL, RET, and ROS1.
Cabozantinib targets cancer cells in multiple ways and has demonstrated significant clinical benefits across several indications, including renal cell carcinoma, hepatocellular carcinoma, and advanced prostate cancer.
Apart from cabozantinib, Exelixis also has several other product candidates in its pipeline, including XL092, which is currently in Phase 1 clinical trials for the treatment of solid tumors, and XL102, which is being developed for the treatment of hematologic malignancies.
Exelixis has partnerships with several leading pharmaceutical companies, including Bristol Myers Squibb, Roche, and Merck.
These collaborations are aimed at advancing the development and commercialization of its small molecule therapeutics in various markets around the world.
Overall, Exelixis is a leading player in the field of cancer therapeutics, with a strong focus on innovation, research, and development.
The company is committed to improving the lives of patients with cancer and other serious diseases, and it is well-positioned to continue its growth trajectory in the coming years.
Exelixis Inc. is a prominent biotechnology company focused on developing and commercializing innovative cancer therapies. Its portfolio includes a variety of segments, products, and services specifically designed to address the needs of cancer patients and healthcare providers. Below is an extensive overview of its offerings:
1. Cabometyx (cabozantinib)
Cabometyx is Exelixis flagship product, recognized for its pivotal role in treating various types of advanced cancer. It is an oral, small-molecule therapy that primarily targets kidney cancer (renal cell carcinoma) and hepatocellular carcinoma (liver cancer), as well as medullary thyroid carcinoma.
Mechanism of Action:
Cabometyx works by inhibiting multiple receptor tyrosine kinases (RTKs), which are involved in tumor growth and angiogenesis (the formation of new blood vessels that supply the tumor). Its action disrupts critical signaling pathways that cancer cells exploit for survival and proliferation, effectively slowing down or halting cancer progression.
Indications:
- Advanced Renal Cell Carcinoma: Approved for first-line treatment and in previously treated patients.
- Hepatocellular Carcinoma: Approved in certain populations following prior treatments.
- Medullary Thyroid Carcinoma: Approved for use in specific cases.
Cabometyx has been well-received in various international markets, including the United States, Europe, and Japan, demonstrating a strong efficacy profile and an established safety record, often allowing it to be utilized as a standard of care in many treatment regimens.
Cometriq (cabozantinib)
Cometriq is specifically indicated for the treatment of medullary thyroid carcinoma (MTC). This oral therapy is designed for patients who have previously undergone surgical intervention but still require ongoing treatment to manage their cancer effectively.
Mechanism of Action:
Similar to Cabometyx, Cometriq functions by targeting specific RTKs associated with the growth and survival of cancer cells. Its selective action provides a therapeutic option specifically tailored for MTC, which is characterized by its unique molecular and pathophysiological features.
Indications:
- Medullary Thyroid Carcinoma: It is only approved for patients with MTC following surgical resection of the tumor, allowing for more effective management of residual disease.
Collaborative Research and Development
In addition to its proprietary products, Exelixis actively engages in collaborative research and development initiatives within the pharmaceutical industry. This includes a range of services aimed at supporting external partners as they navigate the complexities of drug development.
Services Offered:
- Preclinical and Clinical Research Support: Providing expertise and resources to assist in the design, implementation, and analysis of clinical trials.
- Drug Discovery and Analysis: Offering insights and guidance on potential therapeutic compounds, leveraging Exelixis’s extensive research capabilities and extensive database of drug discovery.
These collaborations often lead to shared advancements in oncology treatments, ultimately contributing to enhanced therapeutic options available for patients.
Cabozantinib
Apart from being a component of both Cabometyx and Cometriq, cabozantinib itself is a promising research compound utilized in ongoing investigations and development efforts. Exelixis provides cabozantinib as a research tool to partnering pharmaceutical companies.
Research Applications:
- Development of New Formulations: Exploring potential new indications for cabozantinib in combination with other therapies.
- Mechanistic Studies: Conducting fundamental research to better understand the pharmacodynamics and pharmacokinetics of cabozantinib.
Diagnostic Tests
Exelixis also focuses on diagnostic services aimed at cancer stratification and treatment optimization. The company has developed a suite of diagnostic tests to assist healthcare professionals in accurately identifying and diagnosing various cancers.
Key Diagnostic Offerings:
- Thyroid Cancer Tests: Products designed to detect and characterize thyroid malignancies, aiding in more precise therapeutic strategies.
- Prostate Cancer Tests: Tests that assess specific biomarkers to differentiate between various stages or aggressiveness of prostate cancer.
These diagnostics are critical for effective patient management, enabling healthcare providers to make informed decisions about treatment approaches based on genetic and molecular characteristics of tumors.
Conclusion
Exelixis Inc. stands at the forefront of oncology drug development and support services, characterized by an unwavering commitment to improving patient outcomes. Through its innovative therapies, collaborative research efforts, and advanced diagnostic tools, Exelixis seeks to deliver comprehensive solutions that address the complexities of cancer treatment, ultimately aiming to enhance the quality of life for cancer patients globally.
1. Cabometyx (cabozantinib)
Cabometyx is Exelixis flagship product, recognized for its pivotal role in treating various types of advanced cancer. It is an oral, small-molecule therapy that primarily targets kidney cancer (renal cell carcinoma) and hepatocellular carcinoma (liver cancer), as well as medullary thyroid carcinoma.
Mechanism of Action:
Cabometyx works by inhibiting multiple receptor tyrosine kinases (RTKs), which are involved in tumor growth and angiogenesis (the formation of new blood vessels that supply the tumor). Its action disrupts critical signaling pathways that cancer cells exploit for survival and proliferation, effectively slowing down or halting cancer progression.
Indications:
- Advanced Renal Cell Carcinoma: Approved for first-line treatment and in previously treated patients.
- Hepatocellular Carcinoma: Approved in certain populations following prior treatments.
- Medullary Thyroid Carcinoma: Approved for use in specific cases.
Cabometyx has been well-received in various international markets, including the United States, Europe, and Japan, demonstrating a strong efficacy profile and an established safety record, often allowing it to be utilized as a standard of care in many treatment regimens.
Cometriq (cabozantinib)
Cometriq is specifically indicated for the treatment of medullary thyroid carcinoma (MTC). This oral therapy is designed for patients who have previously undergone surgical intervention but still require ongoing treatment to manage their cancer effectively.
Mechanism of Action:
Similar to Cabometyx, Cometriq functions by targeting specific RTKs associated with the growth and survival of cancer cells. Its selective action provides a therapeutic option specifically tailored for MTC, which is characterized by its unique molecular and pathophysiological features.
Indications:
- Medullary Thyroid Carcinoma: It is only approved for patients with MTC following surgical resection of the tumor, allowing for more effective management of residual disease.
Collaborative Research and Development
In addition to its proprietary products, Exelixis actively engages in collaborative research and development initiatives within the pharmaceutical industry. This includes a range of services aimed at supporting external partners as they navigate the complexities of drug development.
Services Offered:
- Preclinical and Clinical Research Support: Providing expertise and resources to assist in the design, implementation, and analysis of clinical trials.
- Drug Discovery and Analysis: Offering insights and guidance on potential therapeutic compounds, leveraging Exelixis’s extensive research capabilities and extensive database of drug discovery.
These collaborations often lead to shared advancements in oncology treatments, ultimately contributing to enhanced therapeutic options available for patients.
Cabozantinib
Apart from being a component of both Cabometyx and Cometriq, cabozantinib itself is a promising research compound utilized in ongoing investigations and development efforts. Exelixis provides cabozantinib as a research tool to partnering pharmaceutical companies.
Research Applications:
- Development of New Formulations: Exploring potential new indications for cabozantinib in combination with other therapies.
- Mechanistic Studies: Conducting fundamental research to better understand the pharmacodynamics and pharmacokinetics of cabozantinib.
Diagnostic Tests
Exelixis also focuses on diagnostic services aimed at cancer stratification and treatment optimization. The company has developed a suite of diagnostic tests to assist healthcare professionals in accurately identifying and diagnosing various cancers.
Key Diagnostic Offerings:
- Thyroid Cancer Tests: Products designed to detect and characterize thyroid malignancies, aiding in more precise therapeutic strategies.
- Prostate Cancer Tests: Tests that assess specific biomarkers to differentiate between various stages or aggressiveness of prostate cancer.
These diagnostics are critical for effective patient management, enabling healthcare providers to make informed decisions about treatment approaches based on genetic and molecular characteristics of tumors.
Conclusion
Exelixis Inc. stands at the forefront of oncology drug development and support services, characterized by an unwavering commitment to improving patient outcomes. Through its innovative therapies, collaborative research efforts, and advanced diagnostic tools, Exelixis seeks to deliver comprehensive solutions that address the complexities of cancer treatment, ultimately aiming to enhance the quality of life for cancer patients globally.